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ABSTRACT
Questions
• With respect to outcomes such as survival, re-
sponse rate, response duration, time to progres-
sion, and quality of life, is alemtuzumab a
beneficial treatment option for patients with
B-cell chronic lymphocytic leukemia (CLL)?
• What toxicities are associated with the use of
alemtuzumab?
• Which patients are more likely—or less likely—
to benefit from treatment with alemtuzumab?
Perspectives
Evidence was selected and reviewed by one member
of the Hematology Disease Site Group (DSG) of Can-
cer Care Ontario’s Program in Evidence-Based Care
(PEBC) and by methodologists. The practice guide-
line report was reviewed and approved by the Hema-
tology DSG, which comprises hematologists, medical
and radiation oncologists, and a patient representa-
tive. As part of an external review process, the report
was disseminated to obtain feedback from practitio-
ners in Ontario.
Outcomes
Outcomes of interest were overall survival, quality
of life, response rates and duration, and adverse event
rates.
Methodology
A systematic review of the MEDLINE, EMBASE,
HealthStar, CINAHL, and Cochrane Library databases
was conducted to search for primary articles and prac-
tice guidelines. The evidence informed the develop-
ment of clinical practice recommendations. The
evidence review and recommendations were ap-
praised by a sample of practitioners from Ontario,
Canada, and were modified in response to the feed-
back received. The systematic review and modified
recommendations were approved by a review body
within the PEBC.
Results
The literature review found no published random-
ized controlled trials (RCTs) that evaluated alem-
tuzumab alone or in combination with other
chemotherapeutic agents for the treatment of relapsed
or refractory CLL.
One RCT evaluated alemtuzumab administered to
consolidate a complete or partial response to first-
line fludarabine-containing chemotherapy. That study
was stopped early because of excessive grades 3 and
4 infection-related toxicity in the alemtuzumab arm.
Patients receiving alemtuzumab experienced signifi-
cantly improved progression-free survival as com-
pared with patients undergoing observation.
Six single-arm studies evaluated disease response
with administration of alemtuzumab as a single agent
in the treatment of patients with relapsed or refrac-
tory CLL post-fludarabine. The pooled overall re-
sponse rate was 38% (complete response: 6%; partial
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response: 32%). Adverse events associated with the
use of alemtuzumab were commonly reported and
included serious infusion-related, hematologic, and
infection-related toxicities.
Recommendation
This evidence-based recommendation applies to adult
patients with B-cell CLL.
Treatment with alemtuzumab is a reasonable op-
tion for patients with progressive and symptomatic
CLL that is refractory to both alkylator-based and
fludarabine-based regimens.
Qualifying Statements
The evidence supporting treatment with alemtuzumab
comes principally from case series that evaluated dis-
ease response as the primary outcome measure. Pa-
tients should be informed that any possible beneficial
effect of alemtuzumab on other outcome measures
such as duration of response, quality of life, and over-
all survival are not supported in evidence and cur-
rently remain speculative.
Treatment with alemtuzumab is associated with
significant and potentially serious treatment-related
toxicities. Patients must be carefully informed of the
uncertain balance between potential risks of harm and
the chance for benefit reported in studies. Given the
current substantial uncertainty in this balance, patient
preferences will likely play a large role in determin-
ing the appropriate treatment choice.
Given the potential toxicities associated with
alemtuzumab, and given the limited nature of the
agent’s testing in clinical trials in broad populations
of patients with CLL, the use of alemtuzumab in pa-
tients with important comorbidities may be associ-
ated with excessive risks.
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1. QUESTIONS
• With respect to outcomes such as survival, re-
sponse rate, response duration, time to progres-
sion, and quality of life, is alemtuzumab a
beneficial treatment option for patients with
B-cell chronic lymphocytic leukemia (CLL)?
• What toxicities are associated with the use of
alemtuzumab?
• Which patients are more likely—or less likely—
to benefit from treatment with alemtuzumab?
2. CHOICE OF TOPIC AND RATIONALE
With an incidence of 4 per 100,000 population, CLL
is the most common form of adult leukemia in the
Western hemisphere. In patients older than 70 years,
the incidence approaches 50 per 100,000.
Established diagnostic criteria allow CLL to be
differentiated from related subtypes of indolent non-
Hodgkin lymphoma 1. Patients requiring therapy are
usually treated either with systemic alkylator-based
chemotherapy or with a purine analogue (fludara-
bine). Unfortunately, CLL remains incurable with con-
ventional chemotherapeutic approaches, and patients
will relapse even after a favourable response to first-
line therapy.
Several randomized controlled trials (RCTs) in
patients with untreated, advanced-stage CLL have
documented superior response rates and response
duration in patients randomized to fludarabine than
in patients treated with alkylator-based chemo-
therapy 2–4. But despite those encouraging results, an
improvement in overall survival has not been shown.
Patients with disease refractory to standard chemo-
therapy have a particularly poor prognosis, and no
currently accepted standard treatment exists. New
therapies and treatment approaches are needed to
improve outcomes for patients with CLL.
Monoclonal antibodies are an emerging class of
drugs with a unique mechanism of action that repre-
sents a novel approach to cancer treatment.
Rituximab, a humanized anti-CD20 monoclonal an-
tibody, has proven to be particularly effective for
patients with B-cell lymphomas. Alemtuzumab, a
humanized anti-CD52 monoclonal antibody, was the
first of this class of drugs to receive U.S. Food and
Drug Administration approval for use in the treat-
ment of patients with CLL relapsed or refractory to
fludarabine. Alemtuzumab is currently under review
for approval in Canada. Although the function of
CD52 is not known, this antigen is expressed on a
variety of hematopoietic cells, including normal and
malignant T- and B-lymphocytes; CD52 is not ex-
pressed on hematopoietic stem cells. Once bound to
CD52, alemtuzumab induces cell death by one or
more of the following mechanisms:
• Complement-dependent cellular cytotoxicity
• Antibody-dependent cellular cytotoxicity
• Induction of apoptosis
Clinical activity has been demonstrated in heavily
pretreated patients, including those with disease pro-
gression following treatment with fludarabine. How-
ever, the benefits of alemtuzumab are offset by
potential toxicities, including infection-related mor-
bidity and mortality.
Because licensing approval may precede the pub-
lication of phase III studies, the Hematology Disease
Site Group (DSG) felt that a systematic review of the
current literature was needed. This systematic review
will inform further recommendations on this topic
when updated with relevant, high-quality evidence
in the future.PRACTICE GUIDELINE SERIES
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3. METHODS
3.1 Review Development
The present systematic review was developed by the
Hematology DSG of Cancer Care Ontario’s Program
in Evidence-Based Care (PEBC). Evidence was selected
and reviewed by one member of the Hematology DSG.
This systematic review is a convenient and up-
to-date source of the best evidence available on
alemtuzumab in CLL. The body of evidence in the
present review primarily consists of mature RCT data,
where available. That evidence forms the basis of a
clinical practice guideline developed by the Hema-
tology DSG. The systematic review and companion
practice guideline are intended to promote evidence-
based practice in Ontario, Canada. The PEBC is edito-
rially independent of Cancer Care Ontario and the
Ontario Ministry of Health and Long-Term Care.
3.2 Literature Search Strategy
A systematic search of the published literature was
conducted to identify all reports relating to the use of
alemtuzumab for the treatment of patients with CLL.
The MEDLINE (1966 to July 2005), CINAHL (1982 to
July 2005), HealthStar (1975 to July 2005), CANCERLIT
(1975 to July 2005), PREMEDLINE (July 2005),
Cochrane Controlled Trials Register (July 2005), and
Cochrane Database of Systematic Reviews (July
2005) databases were searched. In addition, the pro-
ceedings of the annual conferences of the American
Society of Hematology for 1995–2004 and the Ameri-
can Society of Clinical Oncology (ASCO) for 1995–
2005 were searched for relevant abstracts. The
databases of the United Kingdom Coordinating Com-
mittee on Cancer Research Register, Physician Data
Query, National Institute of Health Clinical Trials,
and the European Organization for Research and
Treatment of Cancer were searched for ongoing clini-
cal trials. The National Guidelines Clearinghouse was
searched for clinical practice guidelines.
Only studies published in English were selected
for the literature review. Publications evaluating
alemtuzumab in non-human subjects and those cat-
egorized as “published comments,” “letters,” and
“editorials” were excluded. The reference list from
each selected article was also reviewed. Where it was
deemed necessary, the authors of included publica-
tions were contacted for missing or additional data.
The preliminary literature search was performed
in November 2002; that search was subsequently up-
dated in November 2004 and July 2005. After the pre-
liminary search, the study selection criteria were
amended to exclude studies with fewer than
20 evaluable patients. As a result, studies in the pre-
liminary literature search that had fewer than 20 eval-
uable patients were later removed from the report. The
data from those small studies, had they been included,
would not have significantly affected either the results
or the DSG’s recommendations. For the sake of clarity,
results from the preliminary and updated searches are
presented together in the present systematic review.
3.3 Study Selection Criteria
Articles were selected for inclusion in this system-
atic review if they met the following criteria:
• The study group included patients with CLL.
• The role of alemtuzumab, as a single agent or in
combination with other therapy, was being tested
for either induction or consolidation therapy.
• Any of the following outcomes was being reported:
survival, quality of life, time to progression, re-
sponse duration, response rate, or adverse effects.
• The sample size reached a minimum of 20 evalu-
able patients.
Two independent observers reviewed the title and
abstract of each publication. These observers were
blinded to author name, institution, name of journal,
nature of the paper (full paper or abstract), and re-
sults. The blinded observers then scored each abstract
as follows:
• “Yes” for those that met the inclusion criteria
• “No” for those that failed to meet the inclusion
criteria
• “Maybe” for those about which the observer was
uncertain
If both observers agreed that the abstract met the
inclusion criteria, the complete document, if available,
was retrieved for further analysis. In cases of disagree-
ment, both observers reassessed the blinded abstract
together to achieve consensus. Where consensus could
not be reached, or in cases where both observers scored
the abstract as “maybe,” the full document was re-
trieved and assessed by both reviewers to achieve
consensus regarding eligibility. The reasons that re-
trieved articles were excluded are documented.
3.4 Synthesizing the Evidence
A lack of adequately designed RCTs in the sample
meant that a formal meta-analysis was deemed inap-
propriate. Where possible, response rates from single-
arm studies evaluating similar patient groups were
calculated. Data were pooled using intent-to-treat
groups, and response proportions were computed.
4. RESULTS
4.1 Literature Search Results
The original and updated searches found 527 publi-
cations, with forty of those publications meeting theFRASER et al.
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inclusion criteria. Of those forty citations, eighteen
were subsequently excluded from analysis for these
reasons:
• Duplicate publication (n = 1)
• Anecdotal case reports (n = 3: one report of se-
vere immune thrombocytopenic purpura follow-
ing a 10-week course of alemtuzumab; one report
of gas gangrene 6 weeks after an 8-week course
of alemtuzumab; and one report of a patient with
CLL treated with 3 courses of alemtuzumab over
a 3-year period)
• Evaluation of patients with Sezary syndrome
(n = 1)
• Evaluation of non-clinical outcomes (n = 1: re-
ported T-cell subset recovery after treatment with
alemtuzumab; the clinical outcomes were re-
ported in a separate publication that was included
in the present systematic review)
• Abstracts subsequently published as full papers
(n = 11; all of which, as full papers, met the in-
clusion criteria for the present systematic review)
These twenty-two publications were eligible for
review (Table I):
• Single-arm studies evaluating alemtuzumab as a
single agent in patients with relapsed or refrac-
tory CLL (n = 9: four full papers, five abstracts)
• Studies evaluating alemtuzumab as a single agent
in newly diagnosed patients with previously un-
treated CLL (n = 3: two full papers, one abstract;
the abstract publication reported only preliminary
toxicity data from an RCT comparing alemtuzumab
with chlorambucil as a first-line treatment in CLL)
• Single-arm studies evaluating alemtuzumab in
combination with additional agents for patients
with refractory CLL (n = 3: two full papers, one
abstract)
• Studies evaluating alemtuzumab as consolidation
therapy in CLL patients with a “response” to pre-
vious-line therapy (n = 6: one full paper, five ab-
stracts; the full paper reported results from an RCT
comparing alemtuzumab maintenance therapy
with observation alone in patients with a response
to first-line fludarabine, a trial that was stopped
early because of severe infection-related compli-
cations in the patients randomized to the
alemtuzumab arm)
The remaining citations reported results from
single-arm studies. One publication reported a pooled
analysis for the risk of cytomegalovirus (CMV) reacti-
vation, CMV pneumonia, and CMV-related death in pa-
tients with lymphoid malignancies treated with
alemtuzumab.
Seven published practice guidelines on the man-
agement of CLL were retrieved. Two of those were
excluded from the present report because they were
not published in English. The European Society for
Medical Oncology (ESMO), the German CLL Study
Group, and the Guidelines Working Group of the U.K.
CLL Forum published separate guidelines for the
diagnosis, staging, and treatment of patients with CLL,
all of which included reference to alemtuzumab
therapy. One published practice guideline by Keating
et al. (2004) 26 specifically addressed the use of alem-
tuzumab in CLL.
TABLE I Characteristics of cited trials in chronic lymphocytic leukemia (CLL)
Regimen type CLL population Trials Publication type
(n) Design Full Abstract
Monotherapy Relapsed/refractory 9 Single-arm Keating et al. 2002 5 Rai et al. 2001 6
Rai et al. 2002 7 Fiegl et al. 2003 8
Ferrajoli et al. 2003 9 Stilgenbauer et al. 2004 10
Moreton et al. 2005 11 Osterborg et al. 1997 12
Osuji et al. 2004 13
Previously untreated 1 RCT Hillman et al. 2004 14,a
2 Single-arm Lundin et al. 2002 15
Karlsson et al. 2005 16
Combination therapy Relapsed/refractory 3 Single-arm Faderl et al. 2003 17 Wierda et al. 2004 18
Elter et al. 2005 19
Consolidation therapy Response to prior line 1 RCT Wendtner et al. 2003 20,b
5 Single-arm Montillo et al. 2004 21
Rai et al. 2002 22
O’Brien et al. 2003 23
Liggett et al. 2005 24
Rossi et al. 2004 25
a Reports preliminary toxicity data from an RCT comparing alemtuzumab with chlorambucil for first-line treatment of CLL (response data not
yet reported).
b Trial stopped early because of excessive infection-related toxicity in patients randomized to alemtuzumab.
RCT = randomized controlled trial.PRACTICE GUIDELINE SERIES
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The ESMO guideline lacked
• a description of the methods used to develop its
recommendations;
• specific mention of the response rates, response
durations, and associated toxicities found in the
included studies; and
• explicit indications about which studies informed
which recommendations.
The German CLL guideline was described as a re-
view article and stated that it was a consensus docu-
ment of the German CLL Study Group (with
membership listed). No description of the methods
used to produce the guideline were provided. Two
studies evaluating alemtuzumab were cited within the
text of the document, and those studies were also re-
trieved in the literature search for the present report
(one study was excluded because of the sample size
criterion). Definitive recommendations regarding the
use of alemtuzumab in CLL were not provided in the
German publication.
The U.K. CLL Forum guideline described the
methods used to develop the recommendations and
explicitly indicated which studies informed the vari-
ous recommendations. Outcomes data, including re-
sponse rates, duration of response, and median survival
rates observed in trials were reported. Nine single-arm
studies of alemtuzumab in patients with CLL informed
that guideline. Of those studies, six are included in
our report, and three were excluded because they did
not meet the minimum sample size criterion.
The practice guideline that specifically addressed
alemtuzumab use indicated that it was developed out
of an expert-opinion roundtable on the topic held
August 8–9, 2004). No further description of the
methods used was provided. The Keating et al. guide-
line 26 was informed by evidence from eight trials of
alemtuzumab in CLL, all of which are included in the
present report.
The recommendations of the foregoing practice
guidelines, which concern alemtuzumab use in pa-
tients with CLL, are addressed here in the Discussion
section.
4.2 Outcomes
4.2.1 Question 1
With respect to outcomes such as survival, response
rate, response duration, time to progression, and
quality of life, is alemtuzumab a beneficial treatment
option for patients with B-cell chronic lymphocytic
leukemia (CLL)?
No studies reported quality-of-life outcome data.
Single-Agent Alemtuzumab for Relapsed/Refractory
CLL: Response Rates: The overall response (OR), com-
plete response (CR), and partial response (PR) rates
associated with single-agent alemtuzumab for patients
with relapsed or refractory CLL are summarized in
Table II and include data from nine single-arm stud-
ies. No comparative or randomized studies were avail-
able for analysis. Six trials each evaluated a standard
12-week course of alemtuzumab in patients with re-
lapsed or refractory disease post therapy with
fludarabine 5,6,9,10,12,13. The combined OR rate across
those six trials was 38% (range: 31%–41%), and the
combined CR and PR rates were 6% (range: 1%–10%)
and 32% (range: 26%–38%) respectively. One
study 10 evaluated alemtuzumab administered subcu-
taneously and reported OR and CR rates similar to those
seen in studies with intravenous administration. No
trials directly compared subcutaneous with intra-
venous administration.
Three studies administered alemtuzumab for
longer than 12 weeks. A single-arm study by Moreton
et al. 11 evaluated treatment with alemtuzumab until a
maximal clinical response was achieved in patients
with relapsed or refractory disease post therapy with
fludarabine. Rates of 54%, 35%, and 19% for OR, CR,
and PR respectively were reported for 91 patients treated
for a median of 9 weeks (range: 1–16 weeks). Periph-
eral blood and bone marrow samples were obtained
from all patients before, during, and after alemtuzumab
therapy to evaluate minimal residual disease (MRD) sta-
tus. A highly sensitive and validated four-colour flow
cytometry–based assay was used to define MRD status.
The limit of detection for that assay was approximately
one CLL cell in 104–105 leukocytes 27. In 20% of pa-
tients, an MRD-negative remission was achieved in the
bone marrow and peripheral blood. However, those
patients had a median treatment-free period, before
initiation with alemtuzumab, of 10 months (range: 4–
43 months), and most patients (72%) had no evidence
of lymphadenopathy or splenomegaly before
alemtuzumab treatment. No trials have directly com-
pared different alemtuzumab regimens.
The remaining two studies 7,8 administered
therapy to 16 and 30 weeks respectively, had smaller
sample sizes (24 and 27 patients respectively), and
reported response rates similar to those of the other
studies in the group.
Response Duration: Data on median time to progres-
sion (TTP) were reported in five single-arm studies
evaluating alemtuzumab in patients with disease that
had relapsed after, or was refractory to, fludarabine
therapy (Table II) 5–7,10,11. Fludarabine-refractory dis-
ease was usually defined as either no response to
fludarabine or relapse within 6 months following a
response to fludarabine. The median TTP ranged from
4 months to 10 months.
Moreton et al. 11 compared the median treatment-
free survival (TFS) according to the response to
alemtuzumab (MRD-negative CR, MRD-positive CR, PR,
or no response). Patients achieving MRD-negative CR
had a significantly prolonged TFS as compared with
those having an MRD-positive CR, a PR, or no responseFRASER et al.
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(median TFS not reached: 20 months, 13 months, and
6 months respectively; p < 0.0001). The median TFS
for the entire cohort was not reported.
Survival: Survival data were reported in four single-
arm studies evaluating alemtuzumab in patients with
relapsed or refractory disease post fludarabine
(Table II) 5–7,10. Median overall survival (OS) ranged
from 8 months to more than 2 years.
Moreton et al. 11 compared OS according to re-
sponse to alemtuzumab. Patients achieving an MRD-
negative CR had a significantly prolonged OS as
compared with those having an MRD-positive CR, a PR,
or no response (median OS not reached: 60 months,
70 months, and 15 months respectively; p < 0.0007).
Median OS for the entire cohort was not reported.
Single-Agent Alemtuzumab for Previously Un-
treated  CLL: Response Rates: Two studies investigated
the OR, CR, and PR rates associated with a trial of single-
agent alemtuzumab for patients with previously un-
treated CLL 15,16. Lundin et al. 15 reported an OR rate
of 87% for 38 evaluable patients treated with sub-
cutaneous alemtuzumab for 18 weeks; the CR and PR
rates were 19% and 68% respectively. Most patients
had advanced-stage disease (69% Rai III/IV).
Response Duration: In the trial by Lundin et al. 15,
median time to treatment failure (TTF) had not been
reached at 18 months. In an update of that trial, re-
ported in abstract form, median TTF in responders had
not been reached at 35 months 16. No other trials re-
ported data pertaining to response duration.
Survival: No studies reported OS rates associated with
alemtuzumab therapy for previously untreated pa-
tients with CLL.
Alemtuzumab in Combination with Additional
Agents for Relapsed/Refractory CLL: Response Rates:
Three single-arm studies evaluated alemtuzumab-
containing combination regimens for the treatment
of relapsed or refractory CLL (Table II) 17–19. No trials
directly compared different combination regimens.
One trial, Elter et al. 19, evaluated alemtuzumab in
combination with fludarabine and reported an OR rate
of 83% for 36 evaluable patients. The CR and PR rates
were 31% and 53% respectively.
TABLE II Responses to monotherapy and combination therapy: single-arm trials of alemtuzumab for B-cell chronic lymphocytic leukemia
(CLL)
Reference Intervention a Patients Response (%) TTP (months) OS (months)
[N (n)] b OR CR PR All CR pts. All CR pts.
Monotherapy in relapsed/refractory CLL
Keating et al. 2002 5 (abs.) Alemtuzumab 93 33 2 31 4.7 9.5 16 32
Rai et al. 2001 6 (abs.) Alemtuzumab c 136 40 7 32 3.9 7.3 7.6 13.4
Rai et al. 2002 7 Alemtuzumab for 16 weeks c 24 33 0 33 7.1 19.6 27.5 35.8
Fiegl et al. 2003 8 Alemtuzumab for 30 weeks maximum 27 41 4 37 NR NR NR NR
Ferrajoli et al. 2003 9 Alemtuzumab 42 31 5 26 NR NR NR NR
Stilgenbauer et al. 2004 10 (abs.) Subcutaneous administration 50 (44) 36 2 34 9.7 NR 13.1 NR
Moreton et al. 2005 11 Alemtuzumab to maximum response 91 54 35 19 NR 20 d NR 41 d
Osterborg et al. 1997 12 Alemtuzumab 29 41 4 38 NR NR NR NR
Osuji et al. 2004 13 (abs.) Alemtuzumab e 26 (23) 52 22 30 NR NR NR NR
Monotherapy in previously untreated disease
Hillmen et al. 2004 14 (abs.) Alemtuzumab 149 NR NR NR NR NR NR NR
Lundin et al. 2002 15
Karlsson et al. 2005 16 (abs.) Alemtuzumab administered 41 (38) 87 19 68 18+ 35+ NR NR
subcutaneously for 18 weeks
 vs. chlorambucil 148 NR NR NR NR NR NR NR
Combination therapy in relapsed/refractory CLL
Faderl et al. 2003 17 Alemtuzumab + rituximab f 32 63 6 56 NR NR NR NR
Wierda et al. 2004 18 (abs.) CFAR 31 (21) 52 14 38 NR NR NR NR
Elter et al. 2005 19 Alemtuzumab + fludarabine 36 83 31 53 13 22 36 Not
reached
a Unless otherwise indicated, the intervention was alemtuzumab 30 mg administered intravenously 3 times weekly for 12 weeks.
b N represents the patient population; n is the evaluable patients, if fewer than the patient population.
c Rai 4-stage system.
d Complete remission not reached in patients negative for minimal residual disease. Numbers are for patients positive for minimal residual
disease, with complete remission.
e Regimen details not reported.
f Alemtuzumab administered intravenously twice weekly for up to 8 weeks, plus rituximab (375 mg/m2) administered weekly for 4 weeks.
OR = overall response rate; CR = complete response; PR = partial response; TTP = time to progression; pts. = patients; OS = overall survival;
abs. = abstract; NR = not reported; CFAR = cyclophosphamide 250 mg/m 2 days 3–5, fludarabine 25 mg/m 2 days 3–5, alemtuzumab 30 mg
days 1, 3, 5, rituximab 375–500 mg/m2 day 2.PRACTICE GUIDELINE SERIES
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Faderl et al. 17 reported a 63% OR rate (6% CR,
57% PR) for 32 patients treated with alemtuzumab in
combination with rituximab. Wierda et al. 18 evalu-
ated a regimen consisting of cyclophosphamide,
fludarabine, alemtuzumab, and rituximab adminis-
tered over six 28-day cycles; the overall response rate
was 52% (14% CR, 38% PR).
Response Duration: Elter et al. 19 reported a median
TTP of 13.0 months for the entire patient cohort; for
patients who achieved a CR, median TTP was
21.9 months. No other studies reported data for re-
sponse duration associated with alemtuzumab-con-
taining combination regimens for patients with
relapsed or refractory CLL.
Survival: Elter et al. 19 reported a median OS of
35.6 months. For patients who achieved CR, median
OS was not reached. No other studies reported sur-
vival data.
Alemtuzumab Consolidation for Patients with a
Response to Previous-Line Therapy: Response
Rates: One RCT 20 and four single-arm studies 21–24
reported response rates for alemtuzumab consolida-
tion therapy; Table III summarizes the results. The
German CLL Study Group (Wendtner et al.) pub-
lished results from an open-label, multicentre, ran-
domized phase III trial that compared 12 weeks of
alemtuzumab consolidation with observation in pa-
tients achieving at least a PR after 6 cycles of first-
line fludarabine-containing chemotherapy 20. The
study’s sample size of 90 patients was designed to
have an 80% statistical power to detect a 25% im-
provement in progression-free survival (PFS) at
2 years. The trial was stopped after the accrual of
21 patients because of the occurrence of grades 3 and
4 infections (National Cancer Institute Common Tox-
icity Criteria, version 2.0) in 7 of the first 11 patients
randomized to alemtuzumab consolidation. Of those
11 patients, 2 (18%) improved on their response to
first-line therapy; both patients achieved a PR follow-
ing first-line fludarabine-containing chemotherapy
and improved to a CR following consolidation with
alemtuzumab.
The four single-arm studies evaluating alem-
tuzumab consolidation therapy were reported in ab-
stract form only 21–24. All studies evaluated a 4- to
8-week course of alemtuzumab in patients who had
stable disease or better after first- or second-line che-
motherapy. Response to alemtuzumab consolidation
was generally defined as an improvement in “post-
induction” response status according to National
Cancer Institute Working Group criteria. Overall,
response status improved following alemtuzumab
consolidation. Two studies 21,23 documented an MRD-
negative remission status in 38%–51% of patients,
based on clonality of the immunoglobulin H (IgH)
gene rearrangement by polymerase chain reaction
analysis of samples of peripheral blood or bone mar-
row, or both.
Response Duration: Two studies reported data for re-
sponse duration associated with alemtuzumab consoli-
dation following a response to first- or second-line
chemotherapy 20,23. In the RCT published by the Ger-
man CLL Study Group 20, no progression occurred in
TABLE III Responses to maintenance or consolidation therapy (or both): randomized and single-arm trials of alemtuzumab for chronic lym-
phocytic leukemia (CLL)
Reference CLL population Intervention a Patients Post- Post- Median Median
[N (n)] b induction alemtuzumab TTP OS
OR CR OR CR (mos.) (mos.)
RCTs of alemtuzumab consolidation following first-line chemotherapy
Wendtner et al. 2004 20 PR or better post first-line Alemtuzumab 11 100 9 100 27 Not Not
fludarabine, fludarabine reached reached
+ cyclophosphamide vs. observation 10 100 20 70 20 24.7 c Not
reached
Single-arm studies of alemtuzumab maintenance/consolidation therapy in patients with CLL
Montillo et al. 2004 21 (abs.) PR or better post first-line Alemtuzumab 10 mg 35 100 29 100 83 NR NR
fludarabine subcutaneously, 6 weeks
Rai et al. 2002 22 (abs.) SD or better post first-line Alemtuzumab 6 weeks 56 (36) 55 4 92 27 (42) NR NR
fludarabine
O’Brien et al. 2003 23 (abs.) PR or better post Alemtuzumab 10–30 mg, 58 (49) 100 12 100 28 (33) 24+ NR
chemotherapy 4–8 weeks  in resp.
Liggett et al. 2005 24 (abs.) Response post first-line Alemtuzumab, 4 weeks 29 (21) 100 NR 83 34 NR NR
fludarabine + rituximab
a Unless indicated otherwise, intervention was alemtuzumab 30 mg administered intravenously 3 times weekly for 12 weeks.
b N is the patient population assigned a treatment at the start of the trial; n is the evaluable patients at follow-up, if fewer than the patient
population.
c p = 0.036.
OR = response rate; CR = complete response; TTP = time to progression; mos. = median months;  OS = overall survival; RCT = randomized
controlled trial; PR = partial response; abs. = abstract; NR = not reported; SD = stable disease; resp. = responders.FRASER et al.
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the 11 patients randomized to alemtuzumab consoli-
dation; that results compares with a 24.7-month mean
PFS in the 10 patients randomized to observation (p =
0.036). O’Brien et al. 23 reported a median TTP of more
than 24 months in patients who demonstrated a re-
sponse to alemtuzumab consolidation.
Survival: Survival data associated with the use of
alemtuzumab consolidation therapy were reported in
the RCT published by the German CLL Study Group 20.
Median OS had not been reached in either the
alemtuzumab arm or the observation arm. No other
studies reported survival data.
4.2.2 Question 2
What toxicities are associated with the use of
alemtuzumab?
Toxicities associated with the administration of
alemtuzumab were reported in most studies (Table IV).
The most common adverse events can be broadly
grouped into these categories:
• Infusion-related side effects
• Myelosuppression
• Infection-related toxicities
Infusion-related side effects: Infusion-related side
effects were reported in sixteen studies 5–7,9,11,12,14–
20,22–24. They occurred in most patients treated with
intravenous alemtuzumab, were usually grade 1 or 2
in severity, and were manageable with appropriate
supportive care. The prophylactic use of pre-medi-
cations was reported in about one third of the studies
and usually consisted of orally administered acetami-
nophen and antihistamines; corticosteroids were gen-
erally reserved for more severe reactions. Grade 3
or 4 fever, rigour, and nausea were reported in up to
20% of patients; other serious infusion-related tox-
icities were less common. The incidence of infusion-
related side effects was similar regardless of the
population evaluated, tended to be higher and more
severe with the first infusion, and improved with sub-
sequent courses of treatment.
The subcutaneous administration of alemtuzumab
was reported in three trials 10,15,21, and this route was
generally much better tolerated than the intravenous
route used in similar patients (Table IV). Grade 1 or 2
fever (68%) and local injection site reactions (88%)
were reported; grade 3 or 4 reactions of any kind were
rarely reported (fewer than 2% of patients) 15.
Myelosuppression: Data regarding myelosuppression
associated with the use of alemtuzumab were reported
in 10 trials 6,7,9–12,15,18–20. Results for studies evaluating
various disease populations were analyzed separately.
Grades 3 and 4 myelosuppression were common
in studies evaluating alemtuzumab monotherapy for
patients with relapsed or refractory disease 6,7,9–12. The
pooled estimates for grades 3 and 4 neutropenia,
thrombocytopenia, and anemia were 39% (range:
22%–66%), 31% (range: 23%–46%), and 8% (range:
0%–28%) respectively. Similar rates of grades 3 and 4
myelosuppression were reported for studies evaluat-
ing alemtuzumab in combination and in maintenance
or consolidation regimens. Data regarding the co-
administration of hematopoietic growth factors were
not well reported.
Infection-Related Toxicity: Data regarding the inci-
dence of infections in patients treated with alem-
tuzumab were reported in twenty publications 5–20,22,23,
25,28. In thirteen studies, antimicrobial prophylaxis was
administered during alemtuzumab therapy. The most
frequently cited combination was cotrimoxazole to-
gether with antiviral therapy (acyclovir, valacyclovir,
famciclovir) for the prevention of Pneumocystis
carinii pneumonia (PCP) and herpes virus infections.
For the present systematic review, data relating to
infection-related toxicity were analyzed and reported
separately for various study populations.
Single-Agent Alemtuzumab for Relapsed or Refrac-
tory CLL: Data pertaining to infection-related morbid-
ity in patients with relapsed or refractory CLL were
reported in eight studies 5–12. The per capita incidence
of all infections ranged from 30 to 93 per 100 pa-
tients (46 per 100 patients across studies). The inci-
dence of grades 3 and 4 infections ranged from 7 to
36 per 100 patients (18 per 100 across studies), and
infection-related mortality ranged from 0 to 10 per
100 patients (4.5 per 100 across studies).
Grades 3 and 4 infections included disseminated
viral infections [for example, varicella–zoster virus
and herpes simplex virus (HSV)], systemic Candida
infections, mycobacterial reactivation, and invasive
fungal infections (for example, pulmonary aspergillo-
sis, rhinocerebral mucormycosis, and cryptococcal
meningitis and pneumonia). Infection with PCP was
reported, but these cases generally occurred in pa-
tients not receiving prophylaxis.
The incidence of CMV reactivation was reported
in seven of the above-mentioned trials 5,6,8–11,13 and
ranged from 1% to 29% (9% across studies); CMV
pneumonitis was reported in 4 patients (0.8% across
studies). The actual risk of CMV reactivation in this
patient population was not clear because most stud-
ies did not prospectively screen all patients.
Williams et al. 28 retrospectively pooled safety
data in 1538 patients with lymphoid malignancies
treated with alemtuzumab in five single-arm trials and
reported that 3.6% of patients experienced “symp-
tomatic” CMV reactivation, CMV pneumonitis (0.8%),
and CMV-related death (0.2%). Routine prospective
screening of all patients for CMV reactivation was not
performed in those studies. Patients who developed
CMV reactivation were usually treated with intrave-
nous ganciclovir until evidence of viremia resolution.
Ganciclovir therapy was highly effective for treating
CMV reactivation, but because ganciclovir-induced
neutropenia was common, myeloid growth factorsPRACTICE GUIDELINE SERIES
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(for example, granulocyte-colony stimulating factor)
were often co-administered.
Rates of adverse events ranged from 11% to 82%
in the studies. Overall, alemtuzumab therapy was
prematurely discontinued in approximately 20% of
patients because of an adverse event—most often
infection-related complications or myelosuppression,
or both.
Single-Agent Alemtuzumab for Previously Untreated
CLL: In an RCT comparing alemtuzumab to chlorambucil
for newly diagnosed patients with CLL, Hillmen et al. 14
reported a CMV reactivation rate of 15% for all patients
randomized to receive alemtuzumab. All patients with
detectable  CMV reactivation were treated with gan-
ciclovir; no cases of CMV pneumonitis occurred. Other
infection-related toxicities have not yet been reported.
TABLE IV Toxicities associated with alemtuzumab for chronic lymphocytic leukemia (CLL)
Reference Patients Prophylactic Infusion- Cytopenia, grade 3/4 (%) b Infections CMV
(n) antimicrobials related a Neutropenia Thrombo- [% (grade 3/4 %)] [% (disease %)]
cytopenia
Monotherapy in relapsed/refractory CLL
Keating et al. 2002 5 93 Famciclovir, £20 NR NR 55 (27) 8 (0)
TMP/SMX
Rai et al. 2001 6 (abs.) 136 Famciclovir, NR c 22 23 32 (NR) 1.5 (NR)
TMP/SMX
Rai et al. 2002 7 24 Optional £17 59 NR 42 (NR) NR (4)
Fiegl et al. 2003 8 (abs.) 27 NR NR NR NR NR (NR) 15 (0)
Ferrajoli et al. 2003 9 42 Cotrimoxazole, £12 35 41 71 (NR) 29 (0)
valacyclovir
Stilgenbauer et al. 2004 10 (abs.) 50 NR NR (sc) 66 34 NR (24) 14 (0)
Moreton et al. 2005 11 91 Cotrimoxazole, £13 48/30 46 43 (24) 15 (0)
acyclovir,
G-CSF,
ganciclovir
Osterborg et al. 1997 12 29 Optional £3 31 28 93 (17) NR
Osuji et al. 2004 13 (abs.) 26 NR NR NR NR NR 17 (4)
Williams et al. 2001 28 (abs.) 1538 NR NR NR NR NR 3.6 (0.6)
Monotherapy in previously untreated CLL
Hillman et al. 2004 14 (abs.) d 297 NR NR NR NR NR 15 0
Lundin et al. 2002 15, 41 Valacyclovir, £27 4  e 16 e 14 (0) 11 (0)
Karlsson et al. 2005 16 (abs.) fluconazole, (sc)
cotrimoxazole
Combination therapy in relapsed/refractory CLL
Faderl et al. 2003 17 32 Valacyclovir, NR NR NR 52 (NR) 27 (0)
cotrimoxazole
Wierda et al. 2004 18 (abs.) 31 Valacyclovir, NR 23/39 23/16 NR (NR) 24 (0)
cotrimoxazole
Elter et al. 2005 19 36 TMP/SMX, £42 6 3 0 NR (15) 6 (0)
valacyclovir
Maintenance/consolidation therapy in patients with CLL
Wendtner et al. 2004 20,d 21 Cotrimoxazole, 0 64 36 A: NR (64) A: 36 (18)
famciclovir O: 20 (0) O: 0 (0)
Rai et al. 2002 22 (abs.) 56 Acyclovir, NR NR NR NR (33) 22 (0)
cotrimoxazole
O’Brien et al. 2003 23 (abs.) 58 Valacyclovir, 0 NR NR 33 (NR) 21 (0)
cotrimoxazole
Liggett et al. 2005 24 (abs.) 29 F+R: 6 F+R: 26 F+R: 6 NR NR
A: 38 A: 14 A: 7
Rossi et al. 2004 25 (abs.) 35 NR NR NR NR 34 (NR) 57 (0)
a Percentage of patients experiencing grade 3 or 4 infusion-related toxicities, including constipation, dermatitis, diarrhea, dyspnea, edema,
fatigue, fever, headache, hypertension, hypotension, injection site reaction, myalgias, rash, rigour, nausea and vomiting, urticaria.
b Values separated by an oblique (e.g., 48/30) give the percentages of grade 3 and grade 4 events respectively.
c Grade 3 and 4 events may have occurred in this study, but they were not explicitly reported.
d Randomized controlled trials; all other studies are single-arm trials.
e Grades 2 through 4.
CMV = cytomegalovirus; TMP/SMX = trimethoprim/sulfamethoxazole; abs. = abstract; G-CSF = granulocyte-colony stimulating factor; NR = not
reported; sc = subcutaneous administration; F = fludarabine; R = rituximab; A = alemtuzumab; O = observation.FRASER et al.
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Lundin et al. 15 reported CMV reactivation in 4 pa-
tients (11%) treated with subcutaneous alemtuzumab.
One case of PCP occurred in a patient not receiving
prophylaxis. An update describing the long-term fol-
low-up for that patient cohort documented 1 episode
of symptomatic Epstein–Barr virus (infection
21 months post alemtuzumab therapy) 16. No other
serious infections occurred.
Alemtuzumab in Combination with Additional Agents
for Relapsed or Refractory CLL: Faderl et al. 17 docu-
mented infections in 52% of patients with lymphoid
malignancies treated with alemtuzumab in combina-
tion with rituximab; CMV reactivation occurred in 27%.
Infections in CLL patients were not reported separately.
Elter 19 reported data on 36 patients treated with
alemtuzumab in combination with fludarabine; fun-
gal pneumonia (n = 2), CMV reactivation (n = 2), and
infection-related death (n = 1 case of Escherichia coli
sepsis) were the only reported infection-related
complications.
Wierda et al. 18 reported CMV reactivation in 24%
of patients (n = 21) treated with alemtuzumab in com-
bination with cyclophosphamide, rituximab, and
fludarabine.
Alemtuzumab Consolidation for Patients with a Re-
sponse to Previous-Line Therapy: Wendtner et al. 20
randomized patients with a response to first-line
fludarabine-containing chemotherapy to consolida-
tion with alemtuzumab (30 mg intravenously 3 times
weekly for 12 weeks) or observation. Explicit stop-
ping rules were determined a priori and included
grade 3 or 4 infection occurring in 5 of the first 10 pa-
tients accrued to the alemtuzumab arm. The study
was stopped early because of severe infections in 7 of
11 patients randomized to alemtuzumab consolida-
tion. Grades 3 and 4 infections included CMV reacti-
vation (n = 2), CMV pneumonitis (n = 2), pulmonary
aspergillosis and HSV/human herpes virus 6 (n = 1),
pulmonary tuberculosis (n = 1), and herpes zoster
reactivation (n = 1). An additional 2 patients devel-
oped grade 2 CMV reactivation. Overall, 9 of 11 pa-
tients (82%) randomized to alemtuzumab
consolidation discontinued therapy because of an
adverse event (severe infection in 5 patients and se-
vere myelosuppression in 4 patients).
Four additional single-arm studies reported in-
fection-related toxicity for alemtuzumab consolida-
tion therapy 22–25. Reactivation of CMV was common,
occurring in 21%–57% of patients; the single reported
case of CMV pneumonitis 22 contributed to patient
death. The studies evaluated either a 10-mg or 30-mg
dose of alemtuzumab administered over 6 to 8 weeks.
No apparent difference in the rate or severity of in-
fections by treatment regimen was observed.
4.2.3 Question 3
Which patients are more likely—or less likely—to
benefit from treatment with alemtuzumab?
Statistical evaluations for independent predictors
of response, response duration, or survival were not
reported in any study—including in the present sys-
tematic review. However, several publications re-
ported subgroup analyses and clinical observations
for patients who were more or less likely to respond
to alemtuzumab.
Several authors noted that patients with lymphad-
enopathy, particularly bulky lymph nodes (>5 cm),
were less likely to achieve a clinical response to
alemtuzumab-containing therapy 5,7,11,12,15,20,23.
Keating et al. 5 reported that patients less likely to
respond included those with Rai stage IV disease, with
at least 1 lymph node greater than 5 cm in diameter,
or with a World Health Organization (WHO) perfor-
mance status of 2. Moreton et al. 11 evaluated alem-
tuzumab monotherapy administered to maximal
response in patients relapsed or refractory to fludar-
abine and reported that patients were significantly
less likely to respond if their lymph nodes were larger
than 5 cm (p < 0.0001), if they had received 3 or more
previous lines of therapy (p = 0.0005), or if their pre-
treatment WHO performance status was greater than 1.
The  RCT published by the German CLL Study
Group 20 failed to find a correlation between response
status and age, disease stage, response to previous-
line fludarabine-containing chemotherapy, cumula-
tive alemtuzumab dose, duration of alemtuzumab
therapy, IgH mutational status, or cytogenetic aber-
rations. However, their analysis was limited to just
11 patients, because the trial was stopped early be-
cause of excessive severe infections in the alem-
tuzumab-consolidation arm.
5. DISCUSSION
In its deliberations, the Hematology DSG places par-
ticular emphasis on
• results from published RCTs (where available);
• recognition of a hierarchy of outcomes that should
influence treatment decisions, with priority given
to therapies found to extend life or improve qual-
ity of life; and
• the potential toxicities associated with treatment,
with particular emphasis on the toxicities seen in
the patients most likely to make up the popula-
tion eventually to be treated.
The members of the Hematology DSG had con-
siderable difficulty reaching consensus on the appro-
priate wording of the recommendation for a potential
indication for alemtuzumab in patients with CLL. The
recommendation went through multiple iterations (see
Section 6.4). Based on their review of the available
evidence, the DSG considered several interpretations
for the use of alemtuzumab in patients with CLL.
The DSG regards alemtuzumab to be an active
agent for the treatment of patients with relapsed orPRACTICE GUIDELINE SERIES
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chemotherapy-refractory CLL. That conclusion is
based on response data from single-arm studies that
report a PR in approximately one third of patients (rec-
ognizing that CR are uncommon). From the perspec-
tive of drug or multi-agent regimen development,
these data are extremely promising and warrant fur-
ther testing of alemtuzumab.
In their deliberations, the DSG cited these factors
as leading to the current recommendation on
alemtuzumab:
• Lack of data from properly designed RCTs
• A paucity of data suggesting improved response
duration, quality of life, or improved overall sur-
vival when alemtuzumab is compared with alter-
native treatment approaches
• Significant potential toxicity, particularly infec-
tion-related morbidity and mortality
Given the anticipated toxicity, data from RCTs
demonstrating improvement in clinically meaning-
ful outcome measures—for example, time to progres-
sion, quality of life, or overall survival—are required
before recommendations permitting the routine use
of alemtuzumab in this patient population can be
made.
The practice guidelines published by ESMO 29 and
the U.K. CLL Forum 30 made recommendations re-
garding the use of alemtuzumab in previously treated
patients. The ESMO guideline recommends alem-
tuzumab as an option for patients with refractory dis-
ease following first-line therapy, based on the
lowest-level evidence (ASCO level V: small case-series).
In addition, the U.K. CLL Forum guideline recom-
mends alemtuzumab for use in patients without bulky
lymphadenopathy (<5 cm) who have been previously
treated with alkylating agents and who are refractory
to fludarabine. The evidence informing the U.K. CLL
Forum recommendation was similar to the evidence
contained in the present report and comprised data
from a smaller selection of single-arm studies.
The German CLL Study Group determined that
definitive recommendations could not be made re-
garding alemtuzumab use and indicated that further
testing in clinical trials would be preferred 31.
Keating et al. 26 did not make explicit recommen-
dations regarding the appropriateness of alemtuzumab
use in CLL patients, but implied that alemtuzumab is
appropriate in fludarabine-refractory patients. Those
authors also stated that advanced age should not be a
contraindication to alemtuzumab use.
The Hematology DSG considered the above rec-
ommendations to be based on low levels of evidence
and, initially, DSG members were not convinced that
these recommendations could inform best clinical
practice. Instead, the DSG initially concluded that po-
tential benefits (response rates in a minority of pa-
tients; uncertain benefit in terms of response duration,
overall survival, and quality of life) were offset by
the potential for significant toxicity. Therefore, an
initial recommendation was developed to indicate that
the data were insufficient to support the routine use
of alemtuzumab in patients with CLL. The DSG ac-
knowledged the potential controversy that could re-
sult from issuing a “non-permissive” recommendation
regarding alemtuzumab use and the potential impli-
cations that such a recommendation might have for
drug availability. The DSG was aware that its recom-
mendations differed from those of other existing prac-
tice recommendations, including those published by
ESMO and the U.K. CLL Forum.
The DSG was also aware that, within the response
data described in the literature reviewed, responses
reached a magnitude that reporting authors—and
members of the DSG—considered to be clinically im-
portant. Although the precise frequency of the re-
sponses was uncertain (and the best estimate was that
they would be infrequent), the DSG acknowledged that
an opportunity for such a response, even with sub-
stantial risks of toxicity, may be highly desired by
some patients. The DSG attempted to reflect this sen-
timent by indicating that, after balancing the benefits
and risks of treatment, certain patients may wish to
consider a trial of therapy.
The DSG members had concerns with issuing an
unclear and potentially conflicting set of recommen-
dations, but they initially considered this option to
represent the best available alternative, and they there-
fore offered this guidance: For patients with CLL, the
evidence is insufficient to recommend the use of
alemtuzumab outside of clinical trials. The DSG rec-
ognizes that, in highly selected cases, after thorough
consideration of the risks and benefits, a trial of
alemtuzumab might be considered.
Section 6 details the subsequent practitioner feed-
back, and it notes that responding clinicians were
generally in agreement with the synthesis and inter-
pretation of the available literature and the resulting
recommendations. However, a small number of re-
spondents commented on the lack of clarity associ-
ated with the recommendations. As a result, the DSG
members continued the consensus process in an ef-
fort to develop a clearer statement, and the DSG sub-
sequently issued a new set of recommendations. The
redeveloped recommendations state that “treatment
with alemtuzumab is a reasonable option for patients
with progressive and symptomatic CLL that is refrac-
tory to both alkylator-based and fludarabine-based
regimens.” To account for the continued concern
about the level of evidence supporting this recom-
mendation and the potential risk–benefit profile of
the therapy, a detailed set of qualifying statements
was also developed.
6. EXTERNAL REVIEW
The systematic review and practice guideline recom-
mendations were distributed to practitioners in On-FRASER et al.
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tario, Canada, for review and feedback in accordance
with the practice guidelines development cycle 32,33.
6.1 Methods
A sample of 95 hematologists in Ontario received
the survey, which consisted of items evaluating the
methods, results, and interpretive summary used to
inform the draft recommendations and asking whether
the draft recommendations should be approved as a
practice guideline. Written comments were invited.
The practitioner feedback survey was mailed
April 13, 2006, and a complete repeat mailing was
sent thereafter. The Hematology DSG reviewed the
results of the survey.
6.2 Results
A total of 63 responses were received from among
the 95 questionnaires mailed, for a response rate of
66%. Of the 63 respondents, 30 (48%) indicated that
they cared for patients for whom the guideline is rel-
evant, and they completed the survey.
Overall, respondents showed strong support for
the guideline. For questions that addressed issues such
as the rationale for the guideline, the quality of the
guideline, and the clarity of the recommendations, a
substantial majority of respondents (87%–100%) ex-
pressed modest to “strong” support for the report
(1 or 2 on a scale of 1–5, with 1 being “strongly
agree,” 3 being “neither agree or disagree,” and
5 being “strongly disagree”).
With respect to the appropriateness of the rec-
ommendations, a majority of respondents agreed with
the draft recommendations as stated (70%) and with
their appropriateness for the target population (73%).
Some respondents (20%) felt that the recommenda-
tions were excessively rigid and could not be applied
to individual patients.
Respondents varied in their views regarding the
clinical utility of the recommendations. Approximately
half responded ambivalently when asked if the rec-
ommendations would produce more benefit than harm.
Responses on whether the recommendations provided
options that would be acceptable to patients varied
widely (31% agreed, 38% were ambivalent, and 31%
disagreed). Most respondents (69%) replied
ambivalently when asked if the effect of the recom-
mendations on patient outcomes would be obvious.
When asked to compare these recommendations
with current practice, approximately half of the re-
spondents felt that the questions were not applicable.
More than half of the respondents (57%) would be
comfortable with their patients receiving the care rec-
ommended in the draft document, and a sizable ma-
jority (70%) felt that the draft report should be
approved as a practice guideline.
Most respondents felt that implementing the
recommendations would require no reorganization of
their practice, nor would it be technically challeng-
ing or expensive (57%–67%). About half of the re-
spondents felt that the recommendations would be
supported by a majority of their colleagues (52%),
but many responded ambivalently to that question
(34%).
A strong majority of respondents (79%) indicated
that they would use the guideline in their own prac-
tice and would apply it to their patients (83%).
6.3 Summary of Written Comments
The main points contained in the written comments
were these:
• Two respondents felt that the drug should be made
available to select patients. One respondent felt
that alemtuzumab should be recommended for
use in patients with CLL who are resistant to
fludarabine-containing combination regiments
with marrow infiltration as a primary treatment
indication. This respondent noted that a response
rate of 38% was observed in that subpopulation
in a phase II trial, and that treatment options for
such patients are extremely limited.
• Two respondents commented that the wording
of the recommendation was unusual. One sug-
gested that specific criteria be given for the
highly specific circumstances mentioned in the
recommendation.
• Two respondents agreed that the current recom-
mendation was appropriate and that alemtuzumab
should be used only in a clinical trial situation.
6.4 Modifications/Actions
The Hematology DSG reviewed and discussed the
comments resulting from the practitioner feedback
survey and addressed the written feedback as follows:
• In their deliberations, the members of the DSG were
unanimous in the view that the data included in
the evidence summary were generally of low
methodologic quality and were characterized by
a lack of prospective comparative trials, thereby
precluding the development of a definitive rec-
ommendation to use alemtuzumab in patients with
CLL. However, the DSG acknowledged that there
may be instances in which patients and physi-
cians who are well informed of the risks and un-
certain net clinical benefit might prefer treatment
with alemtuzumab. In addition, individual mem-
bers of the DSG shared anecdotal experiences in-
volving carefully selected patients who derived
benefit from treatment with alemtuzumab. The
DSG is fully aware that anecdotal clinical experi-
ence is not a basis for informing a guideline rec-
ommendation, but the group acknowledged that
such experience is consistent with available dataPRACTICE GUIDELINE SERIES
CURRENT ONCOLOGY—VOLUME 14, NUMBER 3
108
and contributes to the general support of
alemtuzumab as a reasonable option for select
patients who may have few available alternatives.
• In their deliberations, the DSG members acknowl-
edged that the current wording of the draft rec-
ommendation might be viewed as contradictory
and should be revised.
• In their deliberations, the members of the DSG felt
strongly that alemtuzumab is an active agent in
CLL and that it merits continued testing in well-
designed clinical trials. However, the DSG felt that
a recommendation for the use of alemtuzumab
only in the setting of a clinical trial was too re-
strictive and did not take into consideration cli-
nician or patient preferences to use alemtuzumab
in selected circumstances.
6.5 Report Approval Panel Feedback
The final evidence-based report was reviewed and
approved by Report Approval Panel (RAP) of the PEBC
in April 2006. The panel normally consists of two
members, including an oncologist with expertise in
clinical and methodologic issues. However, in this
case, the oncologist member did not participate in
the RAP review process because that individual was
one of the authors of the report. No significant issues
were raised by the other panel member, and the re-
port was approved for distribution.
6.6 Additional Deliberations
The DSG discussed the practitioner feedback and again
reviewed the draft recommendation at its bi-annual
meeting of May 16, 2006. Feedback for the report
was uniformly positive for questions related to the
report development process. In contrast, feedback
relating to several aspects of clinical care were gen-
erally less positive. Some respondents had noted that
the initial draft recommendation could be perceived
as contradictory in nature. Given those concerns, the
members of the DSG felt that the draft recommenda-
tion required revision.
Following a detailed discussion, the DSG reached
consensus on a revised recommendation and issued
the three qualifying statements.
The DSG members remained unanimous in their
view that the data for use of alemtuzumab in CLL are
limited and of low methodologic quality. The deci-
sion to revise the draft recommendations was there-
fore not attributable to an alternate interpretation of
the available data. Instead, the major basis for revi-
sion were these:
• Appreciation by the DSG members that, despite
no clear evidence for the inducement of durable
periods of disease control or improvements in
quality of life or overall survival, patients or cli-
nicians or both may prefer to use alemtuzumab
in selected instances. Inherent in this decision is
an understanding that the potential risks could
be substantial and the potential for benefit un-
certain.
• The notion that some patients with few available
treatment alternatives may derive benefit from
treatment with alemtuzumab. The potential ben-
efit was supported anecdotally by members of
the DSG who cited specific examples of carefully
selected patients who derived benefit following
treatment with alemtuzumab.
In summary, the DSG reframed the recommenda-
tion to consider alemtuzumab to be a potential op-
tion for patients whose CLL is refractory to current
standard options (alkylator-based therapy and
fludarabine). The limitations and risks of the
alemtuzumab option are addressed in a series of quali-
fying statements.
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